1. Sequential combination therapies for HBeAg-positive chronic hepatitis B: the search continues

   • Ankur Jindal
   • Manoj Kumar

   Editorial 16 January 2021 Pages: 1 - 3

2. Is it time to spit? More evidence for the oral–gut–liver axis in liver disease

   • Chathur Acharya
   • Jasmohan S. Bajaj

   Editorial 21 January 2021 Pages: 4 - 5

3. Management of primary sclerosing cholangitis and its complications: an algorithmic approach

   • Michal Prokopič
   • Ulrich Beuers

   Review Article Open access 30 December 2020 Pages: 6 - 20

   

4. How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?

   • Yana Geng
   • Klaas Nico Faber
   • Han Moshage

   Review Article Open access 06 February 2021 Pages: 21 - 35

   

5. Regression of portal hypertension: underlying mechanisms and therapeutic strategies

   • Sonia Selicean
   • Cong Wang
   • Jordi Gracia-Sancho

   Review Article Open access 05 February 2021 Pages: 36 - 50

   

6. Efficacy of peg-interferon–nucleoside analog sequential optimization therapy in HBeAg-positive patients with CHB

   • Wei Xu
   • Qiang Li
   • Liang Chen

   Original Article 29 September 2020 Pages: 51 - 59

   

7. Liver damage favors the eliminations of HBV integration and clonal hepatocytes in chronic hepatitis B

   • Gang Hu
   • Ming X. Huang
   • Xiao M. Peng

   Original Article Open access 03 February 2021 Pages: 60 - 70

   

8. Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients

   • Matt Liu
   • Tai-Chung Tseng
   • Mindie H. Nguyen

   Original Article 04 January 2021 Pages: 71 - 81

   

9. Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy

   • Xiaoning Wu
   • Jialing Zhou
   • Jidong Jia

   Original Article 18 January 2021 Pages: 82 - 92

   

10. Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child–Pugh B cirrhosis

    • Jean-Frédéric Blanc
    • Faiza Khemissa
    • for the PRODIGE 21 collaborators

    Original Article 09 January 2021 Pages: 93 - 104

    

11. One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment

    • Tai-Chung Tseng
    • Jonggi Choi
    • Jia-Horng Kao

    Original Article 05 February 2021 Pages: 105 - 113

    

12. S100P as a novel biomarker of microvascular invasion and portal vein tumor thrombus in hepatocellular carcinoma

    • Lu-Nan Qi
    • Liang Ma
    • Le-Qun Li

    Original Article 25 January 2021 Pages: 114 - 126

    

13. Prevalence of nonalcoholic fatty liver disease in mental disorder inpatients in China: an observational study

    • Qiuyue Ma
    • Fude Yang
    • Min Liu

    Original Article Open access 29 January 2021 Pages: 127 - 136

    

14. Sorafenib for advanced hepatocellular carcinoma provides better prognosis after liver transplantation than without liver transplantation

    • Soon Kyu Lee
    • Jeong Won Jang
    • Seung Kew Yoon

    Original Article 26 January 2021 Pages: 137 - 145

    

15. Acute liver failure in Budd–Chiari syndrome and a model to predict mortality

    • Paul J. Thuluvath
    • Joseph J. Alukal
    • Talan Zhang

    Original Article 02 January 2021 Pages: 146 - 154

    

16. Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis

    • Xin Zeng
    • Xia Sheng
    • Wei-Fen Xie

    Original Article 01 January 2021 Pages: 155 - 165

    

17. GATA6 modulates the ductular reaction to bile duct ligation

    • Marjut Pihlajoki
    • Tea Soini
    • David B. Wilson

    Original Article 24 January 2021 Pages: 166 - 178

    

18. Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan

    • Fu-Shun Yen
    • James Cheng-Chung Wei
    • Chih-Cheng Hsu

    Original Article 10 January 2021 Pages: 179 - 190

    

19. Alterations of the salivary and fecal microbiome in patients with primary sclerosing cholangitis

    • Y. Lapidot
    • A. Amir
    • M. Safran

    Original Article 19 September 2020 Pages: 191 - 201

    

20. Implications of liver injury in risk-stratification and management of patients with COVID-19

    • Jiaofang Shao
    • Yuan Liang
    • Ling Lu

    Original Article 06 February 2021 Pages: 202 - 212

    

21. Reductions in liver cirrhosis hospitalizations during the COVID-19 pandemic

    • Jianglei Li
    • Deliang Liu
    • Yuyong Tan

    Letter to the Editor 09 January 2021 Pages: 213 - 214

22. How can we reduce the impact of COVID-19 pandemic on timely access to liver transplantation in children?

    • Mettu Srinivas Reddy
    • Jagadeesh Menon
    • Mohamed Rela

    Letter to the Editor 27 January 2021 Pages: 215 - 216

    

23. Chronic liver disease independently associated with COVID-19 severity: evidence based on adjusted effect estimates

    • Haiyan Yang
    • Jie Xu
    • Yadong Wang

    Letter to the Editor 28 January 2021 Pages: 217 - 222